Hyphens Pharma International, listed on SGX Catalist, has announced a net profit of S$2 million for the first half of 2025, a significant drop from S$5.9 million in the same period last year. The company reported a revenue of S$89.5 million, down from S$99.6 million in 1H2024, primarily due to reduced sales in its Pharmaceutical and Medical Aesthetics segment and its Digital Platform and E-Pharmacy segment.
The company’s proprietary brands, however, achieved a notable 22.5% sales growth, driven by portfolio expansion and increased demand for products like Ceradan® and Ocean Health® supplements. Executive Chairman and CEO Lim See Wah highlighted the impact of external macroeconomic factors, including inflationary pressures and currency depreciation, on the company’s performance. He stated, “We will continue to be diligent in managing the impact of foreign exchange volatility and increased procurement pricing.”
Despite the challenges, Hyphens Pharma improved its gross profit margin to 39.4% from 34.9% in the previous year, thanks to a strategic focus on higher-margin products. The company also launched Winlevi®, a new acne treatment, in Singapore and Malaysia, strengthening its dermatology portfolio.
Looking ahead, Hyphens Pharma aims to continue expanding its proprietary brands and enhancing its digital platforms. The company recently upgraded its POM platform to foster deeper engagement with healthcare professionals. Additionally, Hyphens Pharma increased its stake in Ardence Pharma to 82%, reinforcing its presence in the medical aesthetics market. The company remains committed to its long-term strategy of delivering sustainable value to stakeholders amidst ongoing market volatility.
“`
